From MarketBeat:

Raymond James & Associates purchased 80,706 shares of REGENXBIO Inc. during the third quarter, raising its holdings in the biotech company to 100,620 shares, valued at $1,656,000. 88.80% of the stock is owned by institutional investors. Analysts have rated the stock as a “Moderate Buy” with a consensus price target of $33.71.

REGENXBIO’s stock opened at $13.26 on Friday, with a 50-day simple moving average of $17.88 and a 200-day simple moving average of $17.52. The company reported a negative net margin of 262.18% and a negative return on equity of 59.54% in the third quarter. The firm’s revenue was up 9.1% on a year-over-year basis. It is forecast to post -4.99 EPS for the current fiscal year.

In other news, insider Steve Pakola sold 17,237 shares of the stock in a transaction, and CEO Kenneth T. Mills sold 45,000 shares of the firm’s stock. Insiders have sold a total of 107,237 shares of company stock worth $1,868,451 over the last ninety days. Insiders own 12.70% of the company’s stock.

REGENXBIO Inc is a clinical-stage biotechnology company that provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease based on proprietary adeno-associated virus gene delivery platform.

Please send any questions or comments about this story to [email protected].

(Source: MarketBeat)



Read more: Raymond James & Associates Purchases 80,706 Shares of REGENXBIO Inc. (NASDAQ:RGNX)